Compugen Ltd.
A clinical-stage company developing cancer immunotherapies using an AI platform.
CGEN | TA
Overview
Corporate Details
- ISIN(s):
- IL0010852080
- LEI:
- Country:
- Israel
- Address:
- 26 Harokmim St., Bldg D, 5885849 Holon
- Website:
- https://www.cgen.com/
Description
Compugen Ltd. is a clinical-stage therapeutic discovery and development company specializing in cancer immunotherapy. A pioneer in its field, the company leverages a proprietary, broadly applicable, and predictive AI-powered computational discovery platform to identify novel drug targets. Its primary focus is on developing innovative, first-in-class therapeutics designed to modulate the tumor microenvironment and enhance anti-tumor immune responses. Compugen's mission is to advance its pipeline of drug candidates to address patient populations unresponsive to current immunotherapy treatments.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2020-06-01 15:59 |
Compugen Announces FDA Clearance of IND Application for Phase 1/2
Triple Combi…
|
English | 38.0 KB | ||
| 2020-05-27 15:59 |
Compugen Doses First Patient in COM701 Phase 1 Monotherapy Expansion Cohort
|
English | 143.9 KB | ||
| 2020-05-27 15:59 |
Compugen Doses First Patient in COM701 Phase 1 Monotherapy Expansion Cohort
|
English | 37.8 KB | ||
| 2020-05-06 15:59 |
Compugen Reports First Quarter 2020 Results
|
English | 91.8 KB | ||
| 2020-05-06 15:59 |
Compugen Reports First Quarter 2020 Results
|
English | 37.7 KB | ||
| 2020-04-27 14:59 |
Compugen Presents Data Update from Ongoing Phase 1 Trial of
COM701 at the 2020…
|
English | 79.2 KB | ||
| 2020-04-27 14:59 |
Compugen Presents Data Update from Ongoing Phase 1 Trial of
COM701 at the 2020…
|
English | 38.0 KB | ||
| 2020-04-15 16:04 |
Compugen issued and sold an additional 483,005 ordinary shares pursuant to the …
|
English | 110.5 KB | ||
| 2020-04-15 16:04 |
Compugen issued and sold an additional 483,005 ordinary shares pursuant to the …
|
English | 37.7 KB | ||
| 2020-04-06 15:59 |
Compugen Announces First Patient Dosed in COM902 Phase 1 Trial for
Patients wi…
|
English | 143.0 KB | ||
| 2020-04-06 15:59 |
Compugen Announces First Patient Dosed in COM902 Phase 1 Trial for
Patients wi…
|
English | 38.0 KB | ||
| 2020-03-17 14:06 |
Closing of $75 Million Public Offering of Ordinary Shares
|
English | 134.9 KB | ||
| 2020-03-17 14:06 |
Closing of $75 Million Public Offering of Ordinary Shares
|
English | 37.7 KB | ||
| 2020-03-13 23:19 |
6K-underwriting agreement
|
English | 326.0 KB | ||
| 2020-03-13 23:19 |
6K-underwriting agreement
|
English | 37.7 KB |
Automate Your Workflow. Get a real-time feed of all Compugen Ltd. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Compugen Ltd.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Compugen Ltd. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
